Antiplatelet therapy in acute coronary syndromes

作者：Menozzi Alberto^*; Lina Daniela; Conte Giulio; Mantovani Francesco; Ardissino Diego

来源：Expert Opinion on Pharmacotherapy, 2012, 13(1): 27-42.

DOI：10.1517/14656566.2012.642862

• acute coronary syndromes
• bleeding risk
• clopidogrel
• dual antiplatelet therapy
• ischaemic risk
• personalised medicine
• pharmacogenomics
• prasugrel
• ticagrelor

Introduction: Antiplatelet therapy is the cornerstone of treatment for patients with acute coronary syndromes in the acute phase and in long-term management. Over the last few years, new antiplatelet drugs have been developed and the therapeutic landscape has rapidly evolved. %26lt;br%26gt;Areas covered: We review the available evidence and most recent data concerning all of the principal classes of antiplatelet agents, including aspirin, thienopyridines and glycoprotein IIb/IIIa inhibitors, as well the impact of the new drugs prasugrel and ticagrelor and the available data concerning cangrelor, elinogrel and PAR-1 inhibitors (still under development). %26lt;br%26gt;Expert opinion: This review considers the management of antiplatelet therapy in the light of recent advances, highlighting how to identify patients who will receive the greatest benefit from the older and newer agents, and underscoring the importance of carefully balancing the risks of ischaemia and bleeding in order to improve clinical outcomes. Finally, the paper discusses the potential role of functional and genetic tests in guiding the choice of antiplatelet therapy in a future perspective of %26apos;personalised medicine%26apos;.

• 出版日期2012-1